Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Incadronate, or YM-175, is a nitrogen containing bisphosphonate. Along with being investigated to treat hypercalcemia of malignancy, it has also been investigated in the treatment of myeloma, leukemia, and other... Incadronic acid was first described in the literature in 1991.
- Mechanism
- Curator reviewed · 9 references
Bisphosphonates are taken into the bone where they bind to hydroxyapatite. Bone resorption by osteoclasts causes local acidification, releasing the bisphosphonate, which is taken into the osteoclast by fluid-phase endocytosis. Endocytic vesicles become acidified, releasing bisphosphonates into the cytosol of osteoclasts where they act.
Osteoclasts mediate resorption of bone. When osteoclasts bind to bone they form podosomes, ring structures of F-actin. Disruption of the podosomes causes osteoclasts to detach from bones, preventing bone resorption.
Nitrogen containing bisphosphonates such as incandronate are known to induce apoptosis of hematopoietic tumor cells by inhibiting the components of the mevalonate pathway farnesyl diphosphate synthase, farnesyl diphosphate, and geranylgeranyl diphosphate. These components are essential for post-translational prenylation of GTP-binding proteins like Rap1. The lack of prenylation of these proteins interferes with their function, and in the case of Rap1, leads to apoptosis. incadronate also activated caspases 3, 4, and 7; further contributing to apoptosis.
- Primary indication
- Incadronate has been investigated in the treatment of myeloma, leukemia, and other cancers.Curator reviewed
- Formula / weight
- C8H19NO6P2 · 287.189 g/mol (avg)
- Also known as
- Cimadronate · Incadronate
Resolves to
LWRDQHOZTAOILO-UHFFFAOYSA-NSMILESOP(O)(=O)C(NC1CCCCCC1)P(O)(O)=OWhat you can answer from here — as of August 30, 2026
Which drugs share a target with Incadronic acid, and which of those have an active Phase 3 trial?